On the Record · Alexion Pharmaceuticals
Alexion Pharmaceuticals acquisitions, on the record
The businesses Alexion Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Wilson Therapeutics AB (publ)Word for word“In the second quarter 2018, we completed the acquisition of Wilson Therapeutics AB (publ).” 10-K for 2018 | acquisition | second quarter 2018 | — |
Syntimmune, Inc.Word for word“Under the terms of the agreement, Alexion acquired Syntimmune for an upfront payment of $400.0, with the potential for additional milestone-dependent payments of up to $800.0, for a total value of up to $1,200.0.” 10-K for 2018 | acquisition | — | Under the terms of the agreement, Alexion acquired Syntimmune for an upfront payment of $400.0, with the potential for additional milestone-dependent payments of up to $800.0, for a total value of up to $1,200.0. |
Caelum Biosciences (Caelum)Word for word“In January 2019, we entered into a collaboration agreement with Caelum Biosciences (Caelum) to develop CAEL101 for light chain (AL) amyloidosis.” 10-K for 2018 | agreed acquisition | January 2019 | — |
Achillion Pharmaceuticals, Inc.Word for word“On January 28, 2020, we completed the acquisition of Achillion Pharmaceuticals, Inc. (Achillion).” 10-K for 2019 | acquisition | January 28, 2020 | — |
Synageva BioPharma Corp.Word for word“As of December 31, 2019 , the net book value of our purchased technology includes $2,992.4 associated with the KANUMA intangible asset, which we acquired in the acquisition of Synageva BioPharma Corp.” 10-K for 2019 | acquisition | — | — |
Portola Pharmaceuticals, Inc.Word for word“With the acquisition of Portola Pharmaceuticals, Inc. (Portola) in July 2020, we added the first and only approved Factor Xa inhibitor reversal agent for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.” 10-K for 2020 | acquisition | July 2020 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2016-12-31 | $0 | $10.5 million |
| 2017-12-31 | $0 | — |
| 2018-12-31 | $0 | — |
| 2019-12-31 | $0 | — |
| 2020-12-31 | $2.11 billion | $62.7 million |
Deal filings since 2016
- 2021-07-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-12-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-07-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2020-05-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-01-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-10-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-10-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-06-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Alexion Pharmaceuticals’s annual reports (10-K for 2020, 10-K for 2019, 10-K for 2018) and the financial data it files with the SEC, as of 2021-02-08. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.